2,151
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Bristol Myers Squibb's recently active trials. Comparator arms are excluded.
- KarXT18 trials
- Pumitamig11 trials
- Pembrolizumab9 trials
- Carboplatin8 trials
- Nivolumab8 trials
- Pemetrexed8 trials
Upcoming readouts
Next primary completion dates among Bristol Myers Squibb's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Oct 2026A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Al…Phase 3
- Nov 2026BALSAM-1: A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipo…Phase 3
- Nov 2026A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipo…Phase 3
- Nov 2026A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEP…Phase 3
- Dec 2026A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Al…Phase 3
- Dec 2026AURORA-HFpEF: Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants Wit…Phase 2
Top therapeutic areas
Conditions studied most often across Bristol Myers Squibb's recently active trials.
- Schizophrenia6 trials
- Alzheimer Disease5 trials
- Multiple Myeloma4 trials
- Psychosis Associated With Alzheimer's Disease3 trials
- Non-small Cell Lung Cancer (NSCLC)2 trials
- Alzheimer's Disease2 trials
Bristol Myers Squibb trials
The 50 most significant of Bristol Myers Squibb's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Phase 1 Study of Navlimetostat Tablet FormulationsNCT07544628Navlimetostat | Phase 1 | Locked · track to reveal | OngoingRecruiting | 64 est. | 31 Aug 2026 |
| A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsNCT06730750BMS-986490 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 360 est. | 5 Sept 2026 |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationNCT05609578Adagrasib oral dose of 400 mg twice daily tablets | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 90 est. | 30 Sept 2026 |
| Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical PracticeNCT07663786Nivolumab | — | Locked · track to reveal | OngoingActive, not recruiting | 726 est. | 1 Oct 2026 |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)NCT05511363KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 410 est. | 5 Oct 2026 |
| BALSAM-1A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderNCT06951698KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 274 est. | 1 Nov 2026 |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)NCT06951711KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 274 est. | 2 Nov 2026 |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)NCT06585787KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 406 est. | 24 Nov 2026 |
| Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersNCT07681076KarXT | Phase 4 | Locked · track to reveal | OngoingNot yet recruiting | 225 est. | 30 Nov 2026 |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)NCT06126224KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 500 est. | 9 Dec 2026 |
| AURORA-HFpEFStudy to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)NCT06122779BMS-986435 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 208 est. | 14 Dec 2026 |
| Imaging Study in Metastatic Clear Cell RCC.NCT07671417RYZ512 | Early Phase 1 | Not yet scored | OngoingNot yet recruiting | 10 est. | Dec 2026 |
| A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult ParticipantsNCT07226817BMS-986435 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 140 est. | 17 Dec 2026 |
| A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult ParticipantsNCT07655518BMS-986521 | Phase 1 | Not yet scored | OngoingRecruiting | 12 est. | 27 Dec 2026 |
| Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)NCT07541833Mavacamten | — | Locked · track to reveal | OngoingRecruiting | 36 est. | 31 Dec 2026 |
| SUCCESSOR-1A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)NCT05519085mezigdomide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 810 est. | 10 Jan 2027 |
| A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese ParticipantsNCT07700329BMS-986368 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 16 est. | 23 Feb 2027 |
| A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult ParticipantsNCT07063342Xanomeline/Trospium Chloride Capsule | Phase 1 | Locked · track to reveal | OngoingRecruiting | 72 est. | 29 Mar 2027 |
| A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or LamotrigineNCT07140913Xanomeline/Trospium Chloride | Phase 3 | Locked · track to reveal | OngoingRecruiting | 424 est. | 28 Jun 2027 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid ArthritisNCT07171983BMS-986454 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 46 est. | 28 Jun 2027 |
| A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)NCT06220201CC-97540 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 120 est. | 15 Jul 2027 |
| Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLCNCT07671092RYZ211/212 | Early Phase 1 | Not yet scored | OngoingNot yet recruiting | 40 est. | Jul 2027 |
| A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-ThalassemiaNCT05664737Luspatercept | Phase 2 | Locked · track to reveal | OngoingRecruiting | 189 est. | 16 Jul 2027 |
| GOLSEEK-1Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell LymphomaNCT06356129Golcadomide | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 850 est. | 9 Aug 2027 |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)NCT05980949KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,000 est. | 7 Sept 2027 |
| rechARgeA Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerNCT06764485BMS-986365 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 960 est. | 12 Sept 2027 |
| A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsNCT06764771BMS-986488 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 437 est. | 15 Oct 2027 |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasNCT06090539BMS-986458 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 460 est. | 28 Oct 2027 |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)NCT03331198JCAR017 (lisocabtagene maraleucel) | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 320 est. | 26 Nov 2027 |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)NCT06615479BMS-986393 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 440 est. | 30 Dec 2027 |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaNCT07015242Rituximab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 65 est. | 9 Jan 2028 |
| Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaNCT04143724ACE-536 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 99 est. | 31 Jan 2028 |
| A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesNCT07415031Adagrasib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 170 est. | 16 Feb 2028 |
| A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)NCT06947941KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 325 est. | 21 Feb 2028 |
| First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)NCT07679061Nivolumab plus ipilimumab | — | Locked · track to reveal | OngoingRecruiting | 200 est. | 29 Feb 2028 |
| ELEMENT-MDSELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood TransfusionsNCT05949684Luspatercept | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 402 est. | 24 Mar 2028 |
| A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276BMS-986489 (BMS-986012+Nivolumab) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 530 est. | 6 Apr 2028 |
| A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseNCT06481306BMS-986470 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 224 est. | 30 Apr 2028 |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical TrialsNCT04064060Luspatercept | Phase 3 | Locked · track to reveal | OngoingRecruiting | 665 est. | 12 May 2028 |
| A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)NCT07015983CC-97540 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 89 est. | 17 May 2028 |
| A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)NCT06929273KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 450 est. | 13 Jun 2028 |
| Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)NCT07379827Xanomeline and trospium chloride (KarXT) | — | Locked · track to reveal | OngoingRecruiting | 1,500 est. | 20 Jun 2028 |
| A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid TumorsNCT07160725BMS-986517 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 315 est. | 31 Jul 2028 |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaNCT06121843BMS-986393 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 187 est. | 1 Aug 2028 |
| A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)NCT07492680BMS-986504 | Phase 2 | Locked · track to reveal | OngoingNot yet recruiting | 260 est. | 15 Aug 2028 |
| SOAR-HCMA Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in ChinaNCT07361289Mavacamten | — | Locked · track to reveal | OngoingRecruiting | 500 est. | 22 Aug 2028 |
| MINDSET 2A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)NCT06976203KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 586 est. | 11 Sept 2028 |
| MINDSET 1A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseNCT06976216KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 586 est. | 11 Sept 2028 |
| A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764Pumitamig | Phase 2 | Not yet scored | OngoingNot yet recruiting | 160 est. | 15 Sept 2028 |
| A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaNCT06882785KarXT | Phase 3 | Locked · track to reveal | OngoingRecruiting | 250 est. | 23 Sept 2028 |